

PENDING CLAIMS 12/14/04

25. The depot medicament formulation of claim 24, wherein the average particle diameter is in the range from 50 to 150 μm .

26. The depot medicament formulation of claim 18, characterized in that it comprises ceramic granules, or calcium phosphates, or both, which have been compressed together to give a shaped article and which have then been coated with the blood plasma protein.

27. The depot medicament formulation of claim 26, wherein the blood plasma protein coating further comprises antibiotics, or growth factors, or both.

28. The depot medicament formulation of claim 18 or 27, wherein the active ingredient is selected from the group consisting of antibiotics, corticosteroids, antimycotics, neuroleptics, antiepileptics, steroid hormones, anticancer hormones, substances which promote wound healing, cytostatics, immunomodulators, anesthetics, analgesics, peptide hormones, antirheumatics, vaccines, antibodies, nucleic acids, peptides, proteins, growth factors, cells, and combinations thereof.

29. The depot medicament formulation of claim 18, characterized in that it is employed for topical administration.

30. The depot medicament formulation of claim 18, characterized in that it is employed for parenteral administration.

31. The depot medicament formulation of claim 18, characterized in that it is employed for transdermal administration.

32. The depot medicament formulation of claim 26 or 27, characterized in that it is employed as an implant.

33. The depot medicament formulation of claim 32, wherein the implant is a bone replacement.

34. A process for producing the depot medicament formulation of claim 18 comprising:

